Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: Is therapeutic drug monitoring necessary?

Journal of Infection and Chemotherapy

Volumn 19, Issue 4, 2013, Pages 732-739

  Falcone, Marco ^a   Russo, Alessandro ^a   Cassetta, Maria Iris ^b   Lappa, Angela ^c   Tritapepe, Luigi ^d   D'Ettorre, Gabriella ^a   Fallani, Stefania ^b   Novelli, Andrea ^b   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AUC MIC; Daptomycin; Pharmacokinetic; Staphylococcal infections; Therapeutic drug monitoring

Indexed keywords

DAPTOMYCIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GRAM POSITIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; INTENSIVE CARE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OSTEOMYELITIS; PROSTHESIS INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION;

ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DAPTOMYCIN; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84882262522     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0559-z     Document Type: Article

References (23)

1. Campanile F, Bongiorno D, Falcone M, Goglio A, Pasticci B, Perez M, et al. Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis. 2012;31:739-45.
2. Venditti M, Falcone M, Micozzi A, Carfagna P, Taglietti F, Serra PF, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica. 2003;88:923-30.
3. Falcone M, Micozzi A, Pompeo ME, Baiocchi P, Fabi F, Penni A, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother. 2004;16:540-8.
4. Falcone M, Campanile F, Giannella M, Borbone S, Stefani S, Venditti M. Staphylococcus haemolyticus endocarditis: clinical and microbiological analysis of four cases. Diagn Microbiol Infect Dis. 2007;57:325-31.
5. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. Infection. 2012;40:527-35.
6. Orsi GB, Falcone M, Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther. 2011;9:653-79.
7. Thorne GM, Aler J. Daptomycin; a novel lipopeptide antibiotic. Clin Microbiol. 2002;24:33-40.
8. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
9. Falcone M, Russo A, Pompeo ME, Vena A, Marruncheddu L, Ciccaglioni A, et al. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. Int J Antimicrob Agents. 2012;39:64-8.
10. Falcone M, Serra P, Venditti M. Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians. Eur J Intern Med. 2009;20:343-7.
11. Campanile F, Bongiorno D, Borbone S, Falcone M, Giannella M, Venditti M, et al. In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes. Diagn Microbiol Infect Dis. 2008;61:227-31.
12. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units - causes, outcome, and prognostic factors of hospital mortality: a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med. 1996;24:192-8.
13. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-807.
14. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64:151-8.
15. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-8.
16. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, Fallani S, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother. 2012;5:253-6.
17. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36:318-25.
18. Dvorchick BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to health subjects. Antimicrob Agents Chemother. 2003;47:1318-23.
19. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245-9.
20. Bubalo JS, Munar MY, Cherala G. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(7):3179.
21. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-51.
22. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009;9:617-24.
23. Canut A, Isla A, Betriu C, Gascón AR. Pharmacokinetic- pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis. 2012;31:2227-35.